DOP2020000112A - Derivado de oxi-fluoropiperidina como inhibidor de quinasa - Google Patents

Derivado de oxi-fluoropiperidina como inhibidor de quinasa

Info

Publication number
DOP2020000112A
DOP2020000112A DO2020000112A DO2020000112A DOP2020000112A DO P2020000112 A DOP2020000112 A DO P2020000112A DO 2020000112 A DO2020000112 A DO 2020000112A DO 2020000112 A DO2020000112 A DO 2020000112A DO P2020000112 A DOP2020000112 A DO P2020000112A
Authority
DO
Dominican Republic
Prior art keywords
oxy
kinase inhibitor
fluoropiperidine
derivative
fluoropiperidine derivative
Prior art date
Application number
DO2020000112A
Other languages
English (en)
Inventor
Youn Kim Nam
Ah Jun Sun
Hee Lee Jun
Woo Kim In
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Publication of DOP2020000112A publication Critical patent/DOP2020000112A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invención se refiere a un compuesto representado por la siguiente Fórmula Química 1, o una sal farmacéuticamente aceptable del mismo, y el compuesto según la presente invención puede usarse de manera útil para la prevención o el tratamiento de enfermedades que se asocian con acciones inhibidoras de quinasa.
DO2020000112A 2017-12-28 2020-06-10 Derivado de oxi-fluoropiperidina como inhibidor de quinasa DOP2020000112A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170183061 2017-12-28
PCT/KR2018/016814 WO2019132562A1 (ko) 2017-12-28 2018-12-28 카이네이즈 저해제로서의 옥시-플루오로피페리딘 유도체

Publications (1)

Publication Number Publication Date
DOP2020000112A true DOP2020000112A (es) 2020-08-31

Family

ID=67067864

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2020000112A DOP2020000112A (es) 2017-12-28 2020-06-10 Derivado de oxi-fluoropiperidina como inhibidor de quinasa

Country Status (32)

Country Link
US (1) US11339167B2 (es)
EP (1) EP3733673B1 (es)
JP (1) JP6995428B2 (es)
KR (2) KR102318929B1 (es)
CN (1) CN111527091B (es)
AU (1) AU2018394997B2 (es)
BR (1) BR112020013141B1 (es)
CA (1) CA3084962C (es)
CL (1) CL2020001752A1 (es)
CO (1) CO2020007162A2 (es)
DO (1) DOP2020000112A (es)
EC (1) ECSP20035590A (es)
ES (1) ES2922633T3 (es)
HR (1) HRP20221043T1 (es)
HU (1) HUE059580T2 (es)
IL (1) IL275207B (es)
LT (1) LT3733673T (es)
MA (1) MA51431B1 (es)
MX (1) MX2020006799A (es)
MY (1) MY194468A (es)
NZ (1) NZ764644A (es)
PE (1) PE20201146A1 (es)
PH (1) PH12020551013A1 (es)
PL (1) PL3733673T3 (es)
PT (1) PT3733673T (es)
RS (1) RS63515B1 (es)
RU (1) RU2758370C1 (es)
SA (1) SA520412335B1 (es)
SG (1) SG11202004917UA (es)
SI (1) SI3733673T1 (es)
TN (1) TN2020000082A1 (es)
WO (1) WO2019132562A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200036004A (ko) 2017-08-01 2020-04-06 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 키나아제 억제제로서 피라졸로 및 트리아졸로 비시클릭 화합물
KR102318929B1 (ko) * 2017-12-28 2021-10-28 주식회사 대웅제약 카이네이즈 저해제로서의 옥시-플루오로피페리딘 유도체
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
CN113498352A (zh) 2019-01-23 2021-10-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-三唑并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪
WO2021108803A1 (en) 2019-11-26 2021-06-03 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as jak inhibitors
WO2021147952A1 (zh) * 2020-01-21 2021-07-29 江苏先声药业有限公司 嘧啶并吡咯类化合物
WO2021147953A1 (zh) * 2020-01-21 2021-07-29 江苏先声药业有限公司 嘧啶并五元环类衍生物及其应用
WO2022062601A1 (zh) * 2020-09-22 2022-03-31 江苏先声药业有限公司 嘧啶并吡咯类化合物
CN114315838A (zh) * 2020-09-30 2022-04-12 江苏先声药业有限公司 嘧啶并吡咯类化合物
WO2023165562A1 (zh) * 2022-03-02 2023-09-07 南京明德新药研发有限公司 含氮杂环类化合物及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
US7705004B2 (en) * 2007-08-17 2010-04-27 Portola Pharmaceuticals, Inc. Protein kinase inhibitors
CN103224497A (zh) 2008-04-22 2013-07-31 波托拉医药品公司 蛋白激酶抑制剂
JP5369183B2 (ja) 2008-07-16 2013-12-18 ファーマサイクリックス，インク． 固形腫瘍の治療用のブルートンのチロシンキナーゼの阻害剤
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
DK2975042T3 (en) 2010-06-23 2019-01-21 Hanmi Science Co Ltd Novel fused pyrimidine derivatives to inhibit tyrosine kinase activity
MD20140023A2 (ro) 2011-09-22 2014-06-30 Pfizer Inc. Derivaţi de pirolpirimidină şi purină
RU2018104702A (ru) 2012-08-06 2019-02-22 Ацея Байосайенсиз Инк. Новые соединения пирролопиримидина в качестве ингибиторов протеинкиназ
EP2945636B1 (en) 2013-01-16 2017-06-28 Signal Pharmaceuticals, LLC Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
KR20150113195A (ko) 2013-03-05 2015-10-07 에프. 호프만-라 로슈 아게 브루톤 티로신 키나아제의 억제제
US9840517B2 (en) 2013-09-18 2017-12-12 Beijing Hanmi Pharmaceutical Co., Ltd. Compound inhibiting activities of BTK and/or JAK3 kinases
MD4649C1 (ro) 2013-12-05 2020-04-30 Pfizer Inc. Pirol[2,3-d]pirimidinil, pirol[2,3-b]pirazinil şi pirol[2,3-d]piridinil acrilamide
CN105777756B (zh) * 2014-07-02 2019-03-01 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
CN105732637B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
JP2018537502A (ja) 2015-12-16 2018-12-20 サウザーン リサーチ インスチチュート ピロロピリミジン化合物、キナーゼｌｒｒｋ２阻害剤としての使用、及びその調製方法
EP3950691A1 (en) 2016-06-30 2022-02-09 Daewoong Pharmaceutical Co., Ltd. Pyrazolopyrimidine derivatives as kinase inhibitor
KR102032418B1 (ko) 2017-06-15 2019-10-16 한국화학연구원 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
KR102577241B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
KR102318929B1 (ko) * 2017-12-28 2021-10-28 주식회사 대웅제약 카이네이즈 저해제로서의 옥시-플루오로피페리딘 유도체
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체

Also Published As

Publication number Publication date
CA3084962A1 (en) 2019-07-04
HUE059580T2 (hu) 2022-11-28
IL275207B (en) 2022-09-01
KR20210062618A (ko) 2021-05-31
ECSP20035590A (es) 2020-07-31
US20200308177A1 (en) 2020-10-01
EP3733673A1 (en) 2020-11-04
PT3733673T (pt) 2022-07-18
PH12020551013A1 (en) 2021-08-16
AU2018394997B2 (en) 2021-02-04
EP3733673B1 (en) 2022-06-29
HRP20221043T1 (hr) 2022-11-11
JP6995428B2 (ja) 2022-01-14
SA520412335B1 (ar) 2022-09-19
MX2020006799A (es) 2020-09-03
MA51431B1 (fr) 2022-08-31
CN111527091B (zh) 2023-03-28
JP2021506818A (ja) 2021-02-22
SG11202004917UA (en) 2020-06-29
IL275207A (en) 2020-07-30
SI3733673T1 (sl) 2022-09-30
LT3733673T (lt) 2022-08-10
PL3733673T3 (pl) 2022-09-26
NZ764644A (en) 2023-06-30
KR102318929B1 (ko) 2021-10-28
BR112020013141A2 (pt) 2021-02-23
ES2922633T3 (es) 2022-09-19
CN111527091A (zh) 2020-08-11
MY194468A (en) 2022-11-30
CL2020001752A1 (es) 2020-11-27
KR20190080803A (ko) 2019-07-08
KR102592083B1 (ko) 2023-10-20
US11339167B2 (en) 2022-05-24
MA51431A (fr) 2021-04-07
TN2020000082A1 (en) 2022-01-06
BR112020013141B1 (pt) 2022-03-15
CO2020007162A2 (es) 2020-06-19
CA3084962C (en) 2022-08-09
WO2019132562A1 (ko) 2019-07-04
PE20201146A1 (es) 2020-10-26
RU2758370C1 (ru) 2021-10-28
AU2018394997A1 (en) 2020-06-11
RS63515B1 (sr) 2022-09-30
EP3733673A4 (en) 2021-06-09

Similar Documents

Publication Publication Date Title
ECSP20035222A (es) Derivado de amino-fluoropiperidina como inhibidor de quinasa
CO2020007156A2 (es) Derivado de amino-metil piperidina como inhibidor de quinasa
ECSP18093777A (es) Derivados de pirazolopirimidina como inhibidor de quinasa
DOP2020000112A (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
CO2019004034A2 (es) Compuesto de piridina
CU20160111A7 (es) Compuestos de heterociclilo bicíclico como inhibidores de irak4
ECSP17029203A (es) Inhibidor de cinasa aurora a
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
DOP2019000194A (es) Derivados de pirrolotriazina como inhibidor de cinasas